—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Viatris Inc (VTRS) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for VTRS, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.41 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How VTRS has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.41 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Viatris Inc moved 0.41% on average · correlation 0.12 · higher than 42% of US names
  • Beta, last 3 months 0.59 about the same as over the year
  • On the 10 worst bond days −1.07% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.75% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - Specialty & Generic · United States · 5 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against VTRS on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Viatris Inc

VTRS in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Viatris is a healthcare company that sells prescription brand drugs, generics, complex generics and biosimilars across four regional units covering North America, Europe, Greater China and emerging markets. It supplies treatments spanning cardiovascular, diabetes, oncology, respiratory and other therapeutic areas, and distributes through wholesalers, pharmacies and specialty channels. It also runs collaboration deals with smaller biotech firms to develop and commercialise additional biosimilar products. The company is headquartered in Canonsburg, Pennsylvania, and formed from a merger of a generics business with a branded-drug unit spun out of a larger pharmaceutical company.
Where it sits in the stack
Viatris carries no seat in our AI build-out index; it belongs to the healthcare sector, within the generic and specialty pharmaceutical sleeve of our wider universe, and is not read against the compute stack.
Who it is priced against
The diary has no peer group set for this name; the comparison the market usually draws is with other multinational generics makers such as Teva.
Why Closelooknet tracks it
Viatris holds a seat in the S&P 500 but none in our own indices, carries no Closelooknet score yet, and has not been quoted in the diary's editions.
What the diary watches
Whether the recent lift in analyst price targets is followed by any change in the underlying earnings outlook, which the diary would treat as the more telling signal.

Viatris Inc (VTRS) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: price target by Oppenheimer, 2026-09-23

The Street on this name

Analyst actions and the latest print for VTRS from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Oppenheimer — target 25 Target set to $25 (+45.5% to spot) 2026-09-23
  • Price target Argus — target 20 from 15 Target raised to $20 from $15 (+19.4% to spot) 2026-09-08

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 2.69%, quarterly · last 0.12 USD on 2026-08-21

Dividends and capital return

What VTRS pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.48 USD per share · a 2.69% yield on the 2026-09-25 close 4 distributions, paid quarterly 2026-09-25
  • Change on the year 0.0% against the prior twelve months prior twelve months 0.48 USD per share
  • Last distribution 0.12 USD per share as the price series records it, within days of the ex-date 2026-08-21
  • By calendar year 2023: 0.12 USD (partial) · 2024: 0.48 USD · 2025: 0.48 USD · 2026: 0.36 USD to date first distribution recorded in the three-year window: 2023-11-22

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Viatris Inc (VTRS)?

Viatris Inc trades as VTRS on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is VTRS in a Closelooknet index?

Not currently — Viatris Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does VTRS trade against its moving averages?

Uptrend stack intact: Trades +5.7% vs the 50-day and +18.4% vs the 200-day average, 3% below the 52-week high and +94.3% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Viatris Inc trade when bond yields rise?

Over the past year Viatris Inc had a beta of 0.41 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 42% of US names. On the 10 sessions in which long bonds fell most it moved −1.07% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Viatris Inc do?

Viatris is a healthcare company that sells prescription brand drugs, generics, complex generics and biosimilars across four regional units covering North America, Europe, Greater China and emerging markets. It supplies treatments spanning cardiovascular, diabetes, oncology, respiratory and other therapeutic areas, and distributes through wholesalers, pharmacies and specialty channels. It also runs collaboration deals with smaller biotech firms to develop and commercialise additional biosimilar products. The diary has no peer group set for this name; the comparison the market usually draws is with other multinational generics makers such as Teva.

Where does Viatris Inc sit in the AI build-out?

Viatris carries no seat in our AI build-out index; it belongs to the healthcare sector, within the generic and specialty pharmaceutical sleeve of our wider universe, and is not read against the compute stack. Viatris holds a seat in the S&P 500 but none in our own indices, carries no Closelooknet score yet, and has not been quoted in the diary's editions.

Does Viatris Inc pay a dividend?

Viatris Inc has paid 0.48 USD per share over the last twelve months, paid quarterly, a trailing yield of 2.69% on the 2026-09-25 close; the last distribution recorded in the price series was 0.12 USD on 2026-08-21. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Viatris Inc recently?

The most recent analyst action on Viatris Inc on the Closelooknet wire is a price target by Oppenheimer on 2026-09-23 (target 25). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for VTRS, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.